The Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, has awarded Protein Sciences a contract that is part of the Authority’s medical countermeasures against pandemic influenza and influenza strains with pandemic potential.

Protein Sciences will perform the contract using its proprietary platform technology for producing vaccines that, according to the Food and Drug Administration, has revolutionized influenza vaccine manufacturing and stands to receive up to $610 million through 2021 if BARDA exercises all options.

The Company’s Flublok® (seasonal) and Panblok® (pandemic) influenza vaccines can be made with unprecedented speed, safety and precision. The new contract with BARDA taps into this technology.